arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Sutro Biopharma, Inc.

STRO Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$20.07
Today
as of Sep 4, 16:54 ET
Last 30 days -16.41% Jul 27 → Sep 04
$19.62 $21.25 $22.87 $24.49 $26.12 Jul 27 Aug 04 Aug 12 Aug 19 Aug 27 Sep 04
Open
$20.30
High
$20.43
Low
$19.86
Volume
$124,764
Avg Vol
$205,981
Mkt Cap
$353M
P/E (TTM)
—
Beta
—
52w High
$43.85
52w Low
$7.15
Div Yield
—
Shares Out
$17M

Recent Press Releases & News last 60 days · 2 items

Aug 12 · 20:07 Stocktwits
STRO Stock Plummets 15% — What Drove The Selloff?
Aug 12 · 11:00 PR GlobeNewswire
Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study

Overview

52-week range
$7.15
$44
35% of range
Avg surprise (last 3)
-2.4%
Avg reaction (last 2)
-3.0%
0% positive
Latest IV / EM
187%
EM ±29.1% · $20 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-2.94$-2.24$-1.54$-0.84$-0.14 Actual $-0.85Actual $-0.64Actual $-0.81Actual $-0.59Actual $-0.59Actual $-0.59Actual $-0.91Est $-0.63Actual $-0.14Est $-0.39Actual $-0.67Actual $-2.94Est $-2.32Actual $-2.33 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-76M$-40M$-5M$31M$67M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-2.33 — — — — financials
Thu May 14, 2026Mar/2026 $-2.94 $-2.32 -26.7% -223.1% -3.0% earnings
Tue Sep 30, 2025Sep 2025 $-0.67 — — — — financials
Thu Aug 7, 2025Jun/2025 $-0.14 $-0.39 +64.1% — — earnings
Thu May 8, 2025Mar/2025 $-0.91 $-0.63 -44.4% — -3.0% earnings
Mon Sep 30, 2024Sep 2024 $-0.59 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.59 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.59 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.81 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.64 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.85 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$10M$15M—$10M$64M$17M—$9M
Cost of revenue————————
Gross profit————————
Operating income$-30M$-30M—$-48M$-3M$-69M—$-68M
Net income$-39M$-38M—$-57M$-11M$-76M—$-49M
EPS (diluted)$-2.33$-2.94—$-0.67$-1.35$-9.08—$-0.59

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$54M$74M$58M$66M$64M$106M$190M$175M
Inventory————————
Total current assets$176M$221M$151M$182M$232M$287M$343M$406M
Total assets$194M$242M$174M$210M$262M$321M$387M$452M
Long-term debt————————
Total liabilities$298M$309M$306M$297M$294M$347M$343M$341M
Total equity$-103M$-67M$-132M$-87M$-32M$-26M$45M$111M

Implied volatility — last 90 days

89%208%327%446%565% Jun 07 — IV 166% · EM ±23.0%Jun 08 — IV 174% · EM ±23.0%Jun 09 — IV 182% · EM ±22.8%Jun 10 — IV 182% · EM ±21.5%Jun 11 — IV 180% · EM ±19.9%Jun 12 — IV 224% · EM ±22.9%Jun 15 — IV 243% · EM ±17.6%Jun 16 — IV 287% · EM ±17.0%Jun 17 — IV 438% · EM ±18.3%Jun 19 — IV 128% · EM ±28.4%Jun 22 — IV 133% · EM ±27.7%Jun 23 — IV 142% · EM ±29.1%Jun 24 — IV 132% · EM ±26.5%Jun 25 — IV 160% · EM ±31.3%Jun 26 — IV 131% · EM ±25.1%Jun 29 — IV 149% · EM ±26.4%Jun 30 — IV 149% · EM ±25.7%Jul 01 — IV 151% · EM ±25.2%Jul 02 — IV 151% · EM ±24.5%Jul 03 — IV 157% · EM ±24.5%Jul 06 — IV 147% · EM ±20.4%Jul 07 — IV 170% · EM ±22.4%Jul 08 — IV 167% · EM ±21.0%Jul 09 — IV 162% · EM ±19.2%Jul 10 — IV 169% · EM ±18.7%Jul 13 — IV 224% · EM ±18.7%Jul 14 — IV 327% · EM ±23.7%Jul 15 — IV 326% · EM ±19.2%Jul 16 — IV 535% · EM ±22.3%Jul 20 — IV 124% · EM ±29.3%Jul 21 — IV 134% · EM ±31.1%Jul 22 — IV 136% · EM ±31.2%Jul 23 — IV 137% · EM ±30.7%Jul 24 — IV 153% · EM ±33.9%Jul 27 — IV 157% · EM ±32.7%Jul 28 — IV 141% · EM ±28.9%Jul 29 — IV 143% · EM ±28.7%Jul 30 — IV 148% · EM ±29.0%Jul 31 — IV 149% · EM ±28.5%Aug 03 — IV 153% · EM ±27.1%Aug 04 — IV 135% · EM ±23.2%Aug 05 — IV 144% · EM ±24.1%Aug 06 — IV 151% · EM ±24.4%Aug 07 — IV 156% · EM ±24.4%Aug 10 — IV 174% · EM ±24.1%Aug 11 — IV 165% · EM ±21.8%Aug 12 — IV 214% · EM ±26.8%Aug 13 — IV 215% · EM ±25.3%Aug 14 — IV 143% · EM ±15.8%Aug 17 — IV 242% · EM ±20.2%Aug 20 — IV 566% · EM ±23.6%Aug 24 — IV 89% · EM ±18.7%Aug 25 — IV 107% · EM ±21.9%Aug 26 — IV 139% · EM ±27.9%Aug 27 — IV 114% · EM ±22.3%Aug 28 — IV 115% · EM ±22.0%Aug 31 — IV 142% · EM ±25.2%Sep 01 — IV 101% · EM ±17.4%Sep 02 — IV 124% · EM ±20.6%Sep 03 — IV 161% · EM ±26.1%Sep 04 — IV 187% · EM ±29.1%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in